HUONS GLOBAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21,650 KRW | -1.37% |
|
+0.46% | -8.46% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 664B 486M | Sales 2023 | 758B 554M | Capitalization | 290B 212M |
|---|---|---|---|---|---|
| Net income 2022 | -60.25B -44.05M | Net income 2023 | 38.38B 28.06M | EV / Sales 2022 | 0.22 x |
| Net cash position 2022 | 85.55B 62.54M | Net cash position 2023 | 65.69B 48.02M | EV / Sales 2023 | 0.3 x |
| P/E ratio 2022 |
-3.82
x | P/E ratio 2023 |
7.55
x | Employees | 116 |
| Yield 2022 |
2.67% | Yield 2023 |
2.22% | Free-Float | 39.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.37% | ||
| 1 week | +0.46% | ||
| Current month | +1.17% | ||
| 1 month | -3.13% | ||
| 3 months | -9.41% | ||
| 6 months | +2.12% | ||
| Current year | -8.46% |
1 week
21 550.00
22 050.00
1 month
20 200.0022 750.00
Current year
20 200.0026 500.00
1 year
17 970.0027 250.00
3 years
16 100.0077 238.10
5 years
16 100.0078 380.95
10 years
16 100.00202 751.63
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Tae Yoon
CEO | Chief Executive Officer | 59 | - |
Bo-Young Yun
PSD | President | 59 | - |
Wan-Seob Kim
BRD | Director/Board Member | 60 | 17-03-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Tae Yoon
CEO | Chief Executive Officer | 59 | - |
Bo-Young Yun
PSD | President | 59 | - |
Wan-Seob Kim
BRD | Director/Board Member | 60 | 17-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 21,650 | -1.37% | 11,201 |
| 24-05-09 | 21,950 | 0.00% | 8,610 |
| 24-05-08 | 21,950 | +0.23% | 9,100 |
| 24-05-07 | 21,900 | +0.46% | 14,757 |
| 24-05-03 | 21,800 | +1.16% | 9,796 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
Huons Global Co., Ltd., formerly, Huons Co., Ltd. is Kore-based entity principally engaged in the manufacture and distribution of pharmaceutical products. Along with its subsidiaries, the Company operates its business through two segments: pharmaceutical segment and glass container segment. The pharmaceutical segment produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermines, diet pills and others; capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. The glass container segment produces ampoules, vials, cartridges and caps for used of medicals, foods and cosmetics. The Company also manufactures medical devices such as kits, derma injectors and other injector.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.46% | 194M | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| +20.84% | 2.42B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B |
- Stock Market
- Equities
- A084110 Stock